Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | VNN1 | O95497 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861456 | 1.00 | ALDH1A1 (0.53) | ALDH1A1EPHX2KMT2AKDM5BMEN1 | |
| SCHEMBL5748631 | 1.00 | ALDH1A1 (0.53) | ALDH1A1EPHX2KMT2AKDM5BMEN1 | |
| SCHEMBL5746899 | 1.00 | ALDH1A1 (0.53) | ALDH1A1EPHX2KMT2AKDM5BMEN1 | |
| SCHEMBL5746443 | 0.97 | ALDH1A1 (0.51) | ALDH1A1EPHX2KMT2AKDM5BMEN1 | |
| SCHEMBL3867365 | 0.97 | ALDH1A1 (0.51) | ALDH1A1EPHX2KMT2AKDM5BMEN1 | |
| SCHEMBL3863204 | 0.90 | EPHX1 (0.47) | ALDH1A1EPHX2KMT2AKDM5BMEN1 | |
| SCHEMBL3856965 | 0.87 | KMT2A (0.48) | ALDH1A1EPHX2KMT2AMEN1LMNA | |
| SCHEMBL5909080 | 0.87 | VNN1 (0.53) | ALDH1A1KMT2AMEN1LMNAVNN1 | |
| SCHEMBL5909284 | 0.87 | VNN1 (0.53) | ALDH1A1KMT2AMEN1LMNAVNN1 | |
| SCHEMBL5909117 | 0.87 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1LMNAVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592466-B2 | Ureas having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2009-09-22 | — | — | US | claimed |
| EP-1680415-B1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | claimed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | claimed |
| EP-1680415-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2006-07-19 | — | — | EP | claimed |
| WO-2005035524-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENSIS INHIBITORS | ABBOTT LABORATORIES (US) | 2005-04-21 | — | — | WO | claimed |
| US-7592466-B2 | Ureas having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1680415-B1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680415-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005035524-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENSIS INHIBITORS | ABBOTT LABORATORIES (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | FLT4, FLT1, KDR | ALDH1A1 1710/4885EPHX2 3115/4885KMT2A 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.